Text Size

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00383396
First received: September 29, 2006
Last updated: February 12, 2007
Last verified: February 2007
History of Changes
  Purpose

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.


Condition Intervention Phase
Pterygia
 Drug: Topical Cyclosporine
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Innovative Medical:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • pts with symptomatic pterygia unresponsive to palliative treatment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00383396

Locations
United States, Florida
Dr. Schechter
Boynton Beach, Florida, United States, 33426
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Barry Schechter, MD Florida Eye Microsurgical Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00383396     History of Changes
Other Study ID Numbers: 1963
Study First Received: September 29, 2006
Last Updated: February 12, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Pterygium
Conjunctival Diseases
Eye Diseases
Cyclosporins
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Therapeutic Uses
Dermatologic Agents
Antirheumatic Agents

ClinicalTrials.gov processed this record on June 17, 2013